Earlier this year, the Government of Canada began a public consultation on their 2019 commitment for a national strategy to address high-cost rare drugs. Now, almost seven months after the start of the public consultation and years after their initial commitment, there are few details on the strategy itself or how the government intends to invest $500 million per year set to begin in 2022.

In this episode, Peter Cleary, a Principal at Santis Health, spoke to President and CEO of the Canadian Organization for Rare Disorder (CORD), Durhane Wong-Rieger. They discussed CORD’s advocacy for a health care system that works for those with rare disorders, and the potential of Canada to position itself as a global leader in the rare disease space.